Altitude Related Adverse Health Effects (ARAHE) in Patients With Precapillary Pulmonary Hypertension During 30h Exposure to 2500m

The Impact of Hypoxia on Patients With Precapillary Pulmonary Hypertension and Treatment of Adverse Effects

The interest of journeys to high altitude regions for recreational or professional purposes is increasing, also among potentially vulnerable groups including patients with chronic cardiopulmonary diseases such as pulmonary hypertension (PH). In Switzerland and many other regions worldwide, many settlements and alpine resorts are at altitudes above 1500m and alpine tourism is an important social and economic sector. However, the hypoxic environment at altitude may induce altitude related adverse health effects (ARAHE), including hypoxemia, symptoms of acute mountain sickness (AMS), reduces exercise capacity and increases the pulmonary arterial pressure, which is of particular relevance for patients with chronic hypoxemic respiratory diseases including PH.

On the other hand, advances in disease-targeted medical combination therapies renders PH to the chronic disease groups with many patients surviving for many years with a relatively good quality of live, exercise capacity and low symptom burden. However, data on ARAHE and the exercise capacity of patients with pre-existing PH at altitude is scarce, so that current expert-based guidelines discourage altitude travel for patients with PH. However, we previously showed that the majority of stable PH-patients tolerates normobaric hypoxia or a short trip to 2500m well.

With this project we aim to get profound clinical and pathophysiological insights into the effects of the hypobaric hypoxic environment at altitude during an overnight stay up to 30 hours on the incidence of ARAHE needing oxygen therapy, exercise capacity, pulmonary hemodynamics and sleep in patients with precapillary PH.

We hope that this new valuable data will provide a basis to better counsel PH-patients for potential risk of altitude sojourns.

Study Overview

• Status: Completed
• Conditions: High Altitude Pulmonary Hypertension
• Intervention / Treatment: Procedure: Stay at altitude 2500 m above sea level (high altitude); Procedure: Stay at altitude 470 m above sea level (low altitude)

Detailed Description

Background:

Precapillary PH is defined by right heart catheterization as mean PAP (mPAP) >20 mmHg, pulmonary artery wedge pressure (PAWP) ⩽15 mmHg along with a pulmonary vascular resistance (PVR) ⩾3 wood units (WU). PH is classified into five major groups according to the clinical presentation and response to vasodilator therapies. In the absence of predominant lung disease, the major precapillary PH forms are pulmonary arterial and chronic thromboembolic PH that are the main pulmonary vascular diseases and hereafter summarized as PH.

The leading symptom in PH is dyspnoea on exertion, impaired exercise performance, daily activity and quality of life.With progression of the disease, worsening hemodynamics may lead to gas exchange disturbances associated with hypoxemia, particularly during exercise and sleep. For a long time, the occurrence of PH was associated with a dismal prognosis progressively leading to right heart failure and death within months to a few years. Although PH is still incurable, recent therapeutic advances including medical or interventional therapies have improved the life expectancy, physical performance and quality of life of PH-patients and many patients seen in our daily practice wish to near-normally participate in professional work and recreational activities.

Globally, leisure time and professional activities at high altitude become increasingly popular exposing millions of people to hypobaric hypoxia annually. The alpine tourism in Europe and in other regions worldwide has a long lasting tradition and a relevant number of people have chosen their resident above 1500m above sea level.

Travel to high altitude and altitude-related adverse health effects (ARAHE):

Many Swiss villages and tourist resorts are located at altitudes between 1000 - 2500 m. In America, Asia and Africa, even large settlements are located at these or even higher altitudes and it is estimated that more than 50 million people permanently live above 2500 m. Accordingly, worldwide, millions of people travel regularly to mountain areas for business or recreation and expose themselves to hypobaric hypoxia during days to weeks or even longer. In addition, traveling by airplane, which has become extremely popular, further increased the number of people that are exposed to a hypoxic environment, as the minimally allowed cabin pressure in commercial air travel is equivalent to 2430 m (8000 ft) of altitude and this is often reached in intercontinental flights.

In healthy individuals, altitude exposure acutely induces hyperventilation by hypoxic chemoreceptor stimulation. This mitigates hypoxemia but promotes sleep disturbing high-altitude periodic breathing. About 50% of lowlanders ascending rapidly to >3000 m suffer from acute mountain sickness (AMS) causing headache, loss of appetite, weakness, fatigue and general discomfort. If AMS is not treated by descent, oxygen or medication, it may progress to life-threatening high altitude cerebral oedema. Furthermore, hypoxic pulmonary vasoconstriction (HPV) leads to an elevated PAP at altitude. In 2-4% of mountaineers climbing to 4559 m, excessive PAP-increase triggers high altitude pulmonary edema (HAPE), a non-cardiogenic pulmonary oedema associated with profound, potentially life-threatening hypoxemia, which is treated by oxygen therapy and may be prevented by phosphodiesterase type-5 inhibitor (PDE5i) administration or dexamethasone.

Contribution of this project to the gap in knowledge of the effects of hypoxia in PH:

The proposed trials will provide novel, robust data on the clinical and pathophysiological effects of exposure to a hypoxic environment in patients with PAH/CTEPH. This study will evaluate for the first time safety and tolerability of altitude exposure including an overnight stay in PH-patients and the effect of supplemental oxygen to reverse ARAHE. Close monitoring of patients including during exercise and sleep will provide insight into hypoxia-induced physiological mechanisms and the time course of altitude adaptation. Due to the special geographical location of Switzerland, we have the unique opportunity to study the response to hypobaric hypoxia in patients with PH in excellently suitable and safe settings in the nearby mountains and provide this important data to the scientific community worldwide for the benefit of many PH-patients and their advising caregivers.

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Switzerland
  • Zurich, Switzerland, 8091
    • University Hospital of Zürich

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Informed consent as documented by signature
• PH class I (PAH) or IV (CTEPH) diagnosed according to guidelines: mean pulmonary artery pressure >20 mmHg, pulmonary vascular resistance ≥3 wood units, pulmonary arterial wedge pressure ≤15 mmHg during baseline measures at the diagnostic right-heart catheterization

Exclusion Criteria:

• Resting partial pressure of oxygen <8 kilopascal at Zurich at 490 m low altitude
• Exposure to an altitude >1000 m for ≥3 nights during the last 2 weeks before the study
• Inability to follow the procedures of the study
• Other clinically significant concomitant end-stage disease (e.g., renal failure, hepatic dysfunction)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: SCREENING
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Start with: Stay at altitude 2500 m above sea level (high altitude); Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.	Procedure: Stay at altitude 2500 m above sea level (high altitude); Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.; Procedure: Stay at altitude 470 m above sea level (low altitude); Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.
PLACEBO_COMPARATOR: Start with: Stay at altitude 470 m above sea level (low altitude); Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m as comparator.	Procedure: Stay at altitude 2500 m above sea level (high altitude); Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 2500 m.; Procedure: Stay at altitude 470 m above sea level (low altitude); Patients with precapillary pulmonary hypertension stay a sojourn of 30 h at 470 m.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of altitude-related adverse health effects (ARAHE as defined below) during a sojourn at 2500m, time frame up to 30 h. ARAHE will be defined by any of the following criteria:	Acute mountain sickness with a Lake Louise score >4 including headache, or AMSc score ≥0.7; severe hypoxemia defined as: resting SpO2 <75% for >15 min or <80% for >30 min; exercise SpO2 <75% for >5 min and/or criteria for stopping exercise according to guidelines; intercurrent illness: infection, neurologic, impairment, other new diseases/accidents, requiring medical treatment other than simple measures such as paracetamol; chest pain and/or ECG signs of cardiac ischemia, syncope, tachy- or bradyarrhythmia, severe hyper- or hypotension accompanied by symptoms; dyspnoea at rest and/or any discomfort requiring treatment and/or leading to the wish of a patient to return to low altitude or withdraw from the study	30 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Components of altitude-related adverse health effects	Incidence of individual components of altitude-related adverse health effects	30 hours
Severity of symptoms	Severity of symptoms of acute mountain sickness at 2500 m of high altitude measured by the Lake louise score (LLS) (or Acute Mountain Sickness c questionnaire)	30 hours
Difference in pulmonary artery pressure	Difference in pulmonary artery pressure assessed by the transtricuspid pressure gradient at rest by echocardiography at high vs. low altitude	30 hours
Difference in pulmonary vascular resistance assessed	Difference in pulmonary vascular resistance assessed by the transtricuspid pressure gradient at rest by echocardiography at high vs. low altitude	30 hours
Difference in right ventricular function	Difference in right ventricular function impairment by echocardiography at high vs. low altitude	30 hours
Resting electrocardiography	Prevalence of abnormal resting electrocardiographies (ECG) at high altitude vs. low altitude	30 hours
Exercise electrocardiography	Prevalence of abnormal exercise electrocardiographies (ECG) at high altitude vs. low altitude	30 hours
Blood pressure	Difference in blood pressure at high vs. low altitude	30 hours
Heart-rate variability	Difference in heart-rate variability at high vs. low altitude	30 hours

Collaborators and Investigators

• Sponsor: University of Zurich

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 18, 2021
• Primary Completion (ACTUAL): April 15, 2022
• Study Completion (ACTUAL): April 15, 2022

Study Registration Dates

• First Submitted: October 12, 2021
• First Submitted That Met QC Criteria: October 25, 2021
• First Posted (ACTUAL): November 4, 2021

Study Record Updates

• Last Update Posted (ACTUAL): May 11, 2022
• Last Update Submitted That Met QC Criteria: May 10, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Hypertension; Hypertension, Pulmonary
• Other Study ID Numbers: OVERALP II A

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No